Etavopivat

Thalassemia

Novo Nordisk A/SSmall moleculePhase 3Active

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 89/ 100

Competitive context

21 Active assets in the Thalassemia cohort.

Asset / Sponsor	Phase	Rating
Deferasirox Novartis Pharmaceuticals	Phase 4	BBB
Fludarabine Memorial Sloan Kettering Cancer Center	Phase 2/3	BB
Hydroxyurea Riphah International University	Phase 4	BB
Ppsv23 Fakultas Kedokteran Universitas Indonesia	Phase 4	BB
ZINC SULFATE Fakultas Kedokteran Universitas Indonesia	Phase 4	BB

View all 50 →

Same molecule, other indications

Etavopivat is also rated in:

sickle cell diseaseDormant

B

Indicative ·

60 / 100

Healthy VolunteersDormant

CCC

Indicative ·

52 / 100

Healthy Volunteers Sickle Cell Disease, ThalassemiaDormant

CCC

Indicative ·

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.